Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Observational
Started
2026-07-01
Last updated
2026-05-19
Condition(s) studied
Lung Cancer (NSCLC)
Investigational drug(s) / intervention(s)
Observation
Observation: The patients' second-line treatment received and the follow-up observations were retrospectively collected.
Study summary
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns. It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies. Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence. This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.
Eligibility
Sex
ALL
Min age
1 Year
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Locally advanced or metastatic NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging.
* Previously received advanced first-line treatment based on immune checkpoint inhibitor drugs.
* Has a medical record of disease progression during the first-line treatment.
* Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.
Exclusion Criteria:
* First-line treatment with immune checkpoint inhibitor drugs was ≤ 2 cycles.
* Excluding patients with incomplete key baseline and treatment information.
* Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator
Primary outcome measure(s)
Overall Survival — Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months The overall survival time of the patients enrolled.
Progression Free Survival — Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months The time of disease progression free survival.
Trial sites (3)
Facility
City
Region
Status
Cancer Hospirtal, Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen
Shenzhen
Guangdong
Shanxi Provincial Cancer Hospital
Taiyuan
Shanxi
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.